WuXi Biologics (Cayman) Inc.
2269.HK
Get informed when a big investor buys or sells
+ FollowMarket Cap$223.13B
Close$
$-0.87
101.7% downside
Current Fair Value
101.7% downsideOvervalued by 101.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $223.13 Billion |
|---|---|
| Enterprise Value | $220.44 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $1.16 |
| Beta | 0.62 |
| Outstanding Shares | 4,096,647,224 |
Return
| Return on Equity | 18.99% |
|---|---|
| Return on Assets | 13.96% |
| Return on Invested Capital | 23.49% |
Valuation & Multiples
| P/E Ratio | 37.89 |
|---|---|
| PEG | 1203.87 |
| Price to Sales | 5.13 |
| Price to Book Ratio | 3.94 |
| Enterprise Value to Revenue | 5.09 |
| Enterprise Value to EBIT | 16.41 |
| Enterprise Value to Net Income | 24 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.13 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 25, 2026
EPS Estimate
$0.52
Average shareholder expectationRevenue Estimate
$13.25 B
Average shareholder expectationNext Earnings Call
Expected Date
March 23, 2027
EPS Estimate
$0.85
Average shareholder expectationRevenue Estimate
$16.14 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Wuxi Biologics (Cayman) Inc.
14,705 employees
CEO: Zhisheng Chen Headquartered in Wuxi, China, and established in 2014, WuXi Biologics (Cayman) Inc. delivers a comprehensive, integrated suite of services spanning the entire biologics lifecycle, from initial discovery through development to large-scale...